San Diego-based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug market place in February after revealing promising knowledge from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection As well as in March the